WELL achieved record quarterly revenues of $170.9 million and record Adjusted EBITDA(1) of $27.8 million in Q2-2023. This was WELL’s 18th consecutive quarter of record revenue performance. WELL surpassed a total of… Read More
PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in Australia. VANCOUVER, BC — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF),… Read More
Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024 Seasoned life sciences executive, Mike Kelly, appointed President & CEO… Read More
Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy… Read More
VANCOUVER, BC — /CNW/ — Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies,… Read More
